GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates
– TGM-010 is a naturally occurring, fully-human neuroprotective antibody, with demonstrated ability to cross the BBB, internalize specifically into neurons and engage key stress management machinery to reduce neurological disability – Financing allows GenrAb to emerge from stealth…